Cancer
Malignant Bladder Neoplasm
CI-CAN-00005866Explore in graph →
Top-level346 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005866Explore in graph →
Clinical trials
1,511 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00462488 | Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ | completed | Phase 2 | 46 | Sesen Bio, Inc.INDUSTRY | 2 | May 12, 2020 | clinicaltrials |
| NCT04385316 | Clinical Study of Gastric Cancer, Colorectal Cancer and Bladder Cancer Based on Liquid Biopsy | unknown | — | 3 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT00350688 | Bladder Cancer Chemoradiation Using Intensity Modulated Radiation Therapy | terminated | N/A | 9 | Ottawa Hospital Research InstituteOTHER | 1 | Apr 17, 2020 | clinicaltrials |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.(RITE-USA) | terminated | Phase 3 | 5 | Medical Enterprises Ltd.INDUSTRY | 1 | Apr 15, 2020 | clinicaltrials |
| NCT03986398 | Nosocomial Infections During Total Prostatic Cystectomies (TPC) With Replacement Enterocystoplasty: Prophylactic Role of Urell®, Cranberry Fruit Juice Extract (Vaccicium Macrocarpon)(Cranberry) | terminated | N/A | 10 | Hopital FochOTHER | 1 | Apr 8, 2020 | clinicaltrials |
| NCT00776178 | Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health | completed | — | 68 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2020 | clinicaltrials |
| NCT03534492 | Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)(NEODURVARIB) | completed | Phase 2 | 29 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT01273987 | Neobladder Posterior Wall Suspended With Round Ligament of Uterus | completed | N/A | 76 | Zhiwen ChenOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT04089163 | A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8) | withdrawn | Phase 1 | 0 | Tocagen Inc.INDUSTRY | 0 | Mar 30, 2020 | clinicaltrials |
| NCT04317261 | Role of Novel Urinary Genomic and Metablomic Markers in Diagnosis of Bladder Cancer in Patients With Hematuria | completed | N/A | 181 | Mansoura UniversityOTHER | 1 | Mar 23, 2020 | clinicaltrials |
| NCT02070120 | Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer(CALIBER) | unknown | Phase 2 | 82 | Institute of Cancer Research, United KingdomOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT01076387 | Randomized Trial Comparing Robotic and Open Radical Cystectomy | completed | Phase 3 | 124 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 16, 2020 | clinicaltrials |
| NCT02028442 | Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients(EVOLVE) | completed | Phase 1 / Phase 2 | 61 | Akamis BioINDUSTRY | 2 | Mar 12, 2020 | clinicaltrials |
| NCT02053220 | Mechanism of Action Trial of ColoAd1(MOA) | completed | Phase 1 | 17 | Akamis BioINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02720367 | Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer | completed | Phase 1 | 12 | Taris Biomedical LLCINDUSTRY | 1 | Mar 10, 2020 | clinicaltrials |
| NCT00848627 | Screening for Bladder Cancer | completed | — | 197 | Baylor College of MedicineOTHER | 2 | Feb 25, 2020 | clinicaltrials |
| NCT04212403 | Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)(Prophylaxis001) | completed | N/A | 1,350 | Jessa HospitalOTHER | 1 | Feb 24, 2020 | clinicaltrials |
| NCT04110483 | Thulium Fiber Laser En-bloc Resection vs Conventional Transurethral Resection of Non-muscle-invasive Bladder Cancer | completed | N/A | 130 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Feb 18, 2020 | clinicaltrials |
| NCT02010203 | A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT | terminated | Phase 1 / Phase 2 | 104 | Heat BiologicsINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01094496 | A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) | terminated | Phase 2 | 3 | Celldex TherapeuticsINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03125460 | Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer | completed | — | 424 | CepheidINDUSTRY | 3 | Feb 7, 2020 | clinicaltrials |
| NCT03522155 | Patient-Centered Communication of Life Expectancy Estimates in Genitourinary Malignancies | unknown | N/A | 136 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT04245618 | Neoadjuvant Chemotherapy in Non Muscle Invasive T1b Bladder Cancer | unknown | — | 50 | Assiut UniversityOTHER | 0 | Jan 30, 2020 | clinicaltrials |
| NCT01846520 | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers | completed | N/A | 200 | City of Hope Medical CenterOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT03159585 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | completed | Phase 1 | 6 | Zhujiang HospitalOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00445601 | S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | completed | Phase 3 | 406 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 18, 2020 | clinicaltrials |
| NCT04228198 | Protocol of the Italian Radical Cystectomy Registry | unknown | — | 1,000 | University of Roma La SapienzaOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT03739177 | Onco4D(TM) Biodynamic Chemotherapy Selection for Bladder Cancer Patients | unknown | — | 150 | Animated Dynamics, Inc.INDUSTRY | 1 | Jan 13, 2020 | clinicaltrials |
| NCT04223063 | Exercise-based Pre-habilitation in Bladder Cancer Patients Prior to Radical Cystectomy: a Feasibility Study | unknown | N/A | 20 | Ross MasonOTHER | 0 | Jan 10, 2020 | clinicaltrials |
| NCT01447199 | The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC) | unknown | — | 2,000 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00722553 | Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | completed | Phase 2 | 30 | Acrotech Biopharma Inc.INDUSTRY | 6 | Dec 17, 2019 | clinicaltrials |
| NCT04040725 | Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Dec 17, 2019 | clinicaltrials |
| NCT02178241 | Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 2 | Dec 16, 2019 | clinicaltrials |
| NCT04197414 | Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA | recruiting | — | 3,000 | Yonsei UniversityOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT04194112 | Diagnostic Performance and Predictive Capacity of Immediate Urine Cytology After Transurethral Resection of Non-Muscle Invasive Bladder Cancer; A Prospective Study | completed | N/A | 198 | Mansoura UniversityOTHER | 0 | Dec 12, 2019 | clinicaltrials |
| NCT03715660 | Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation Study | completed | N/A | 198 | Mansoura UniversityOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT04167332 | Prospective Collection of Samples for Urothelial Cancer of Bladder(ProCSUCaB) | not yet recruiting | — | 630 | Universitaire Ziekenhuizen KU LeuvenOTHER | 0 | Nov 18, 2019 | clinicaltrials |
| NCT00880854 | Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer | withdrawn | Phase 1 | 0 | University of Wisconsin, MadisonOTHER | 0 | Nov 15, 2019 | clinicaltrials |
| NCT04162093 | New Technique for Uretero-ileal Anastomosis for Patient With Bladder Cancer Who Are Suitable for Orthotopic Neobladder | completed | N/A | 45 | Ain Shams UniversityOTHER | 0 | Nov 15, 2019 | clinicaltrials |
| NCT02365207 | Intravesical BCG Administration to Patients With Invasive Bladder Cancer | terminated | N/A | 6 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT00005858 | LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer | completed | Phase 1 | 25 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT03156244 | Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients | completed | — | 80 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT03591367 | The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation | completed | N/A | 115 | Mansoura UniversityOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT04148677 | Protoves M1® Syrup in Controlling Adverse Event During HIVEC® Instillations | unknown | — | 100 | Cardarelli HospitalOTHER | 0 | Nov 1, 2019 | clinicaltrials |
| NCT01655745 | Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer | completed | N/A | 22 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 31, 2019 | clinicaltrials |
Data updated 23 days agoSource updated May 12, 2020source: clinicaltrials